SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

Invesco S&P 500 Pure Value ETF offers low valuations, but underperforms peers due to high volatility and expenses. Read what ...

Adjusted per-share earnings in the fourth quarter for UnitedHealth top analysts’ estimates but revenue comes up short.

A recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit ...

UnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving ...

UnitedHealth’s net income plummeted to its lowest level since 2019 amid hefty costs, including some from the Change ...

At the J.P. Morgan Health Care conference, the future outlook for GLP-1 drugs used to treat obesity was a key focus, ...

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

UnitedHealth Group (UHG) has been overcharging some cancer patients by more than 1,000 percent for live-changing drugs, a ...

UnitedHealth posted a better-than-expected profit in the final quarter of 2024, but a nagging rise in medical costs and care ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...